Objectives: The association between Hashimoto’s thyroiditis and BRAFV600E positive papillary thyroid carcinoma (PTC) remains controversial. The aim of this study is to evaluate the effect of Hashimoto’s thyroiditis to survival result of BRAFV600E PTCs using the Cancer Genome Atlas (TCGA) data. Methods:Statistical analysis and genomic analysis were done using gene expression data and clinical data of PTCs in The Cancer Genome Atlas data portal (https://tcga-data.nci.nih.gov) and cancer browser (https://genome-cancer.ucsc.edu). We compared overall survival (OS) and recurrence-free survival (RFS) between BRAFV600E PTCs with Hashimoto’s thyroiditis and BRAFV600E PTCs without Hashimoto’s thyroiditis. Also, using differently expressed genes(DEG) between two groups, we tried to find altered canonical pathways which could explain the effect of Hashimoto’s thyroiditis to BRAFV600Epositive PTCs. Result:When we compared OS and RFS using Kaplan Meier survival curve, BRAFV600E PTCs with Hashimoto’s thyroiditis showed better OS but worse RFS than those of BRAFV600E PTCs without Hashimoto’s thyroiditis (p=0.19 and p=0.05, respectively). As for incidence, BRAFV600Emutation and Hashimoto’s thyroiditis didn’t show any association each other. BRAFV600E PTCs with Hashimoto’s thyroiditis showed lower TNM stage when compared with BRAFV600E PTCs without Hashimoto’s thyroiditis (p=0.05). Several immune related canonical pathways were upregulated and several pathways associated with tumor aggressiveness were downregulated inBRAFV600E PTCs with Hashimoto’s thyroiditis. Conclusion:BRAFV600E PTCs with Hashimoto’s thyroiditis showed better OS but worse RFS when compared to BRAFV600E PTCs without Hashimoto’s thyroiditis. We could explain this survival difference by genomic analysis using gene expression profile and altered pathway analysis.